Retatrutide
10 mg
Triple receptor agonist (GLP-1 / GIP / glucagon) under investigation for metabolic research.
Overview
Retatrutide is a novel investigational triple-receptor agonist that simultaneously targets the GLP-1, GIP, and glucagon receptor pathways. Originating from incretin research programs, it represents a next-generation tool for studying glucose regulation, energy expenditure, and adiposity.
Mechanism of Action
At the cellular level, Retatrutide binds with high affinity to GLP-1 and GIP receptors on pancreatic β-cells, enhancing glucose-dependent insulin secretion, while concurrent glucagon receptor activation in hepatocytes is associated with increased energy expenditure. The combined incretin–glucagon signature differentiates it from single or dual agonists. Receptor-bound Retatrutide initiates cAMP and downstream PKA cascades that modulate appetite regulation centers in the hypothalamus.
Research Findings
Triple Hormone Receptor Agonist Retatrutide for Obesity
NEJM, 2023 (PMID: 37366315)
Phase 2 data describing dose-dependent reductions in body weight markers in preclinical and clinical study cohorts.
GIP/GLP-1/Glucagon Co-agonism
Nature Reviews Endocrinology, 2022
Mechanistic review of triple-agonist receptor pharmacology and metabolic outcomes.
Potential Research Applications
- Glucose homeostasis research
- Energy expenditure and adiposity studies
- Incretin receptor pharmacology
- Comparative agonist profiling